Press Releases

Clinical device expected availability in 2026 Scalable platform launch planned for 2027 [ MIAMI ] — KIFFIK Biomedical Inc. (“KIFFIK”), a leader in interstitial fluid (ISF)-based diagnostics, today announced a strategic manufacturing partnership with Beacon MedTech Solutions to deliver its K-EXP™ platform. The K-EXP™ clinical device is expected to be available in the second half of 2026, with the scalable production of its next-generation device beginning in mid-2027. The partnership marks a shift from development to execution, aligning clinical deployment and large-scale manufacturing within a single, continuous development timeline. “We …

The K-EXP™ platform enables direct access to interstitial fluid for molecular measurement at the source Partnership supports regulatory, clinical, and commercial expansion across Japan and Asia-Pacific [ MIAMI, FL AND TOKYO, JAPAN / ACCESS Newswire ] – KIFFIK Biomedical today announced a strategic alliance with HekaBio K.K. to expand access to interstitial fluid (ISF) across Japan and key Asia-Pacific markets. ISF surrounds living cells and reflects real-time biological activity at the tissue level – where molecular signaling, immune response, and disease progression originate. KIFFIK’s K-EXP™ platform is designed to access …

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations. Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations. August 13, 2025  MDL Strategic Communications PROVIDENCE, RI, August, 12, 2025- KIFFIK Biomedical, Inc. (“Kiffik”), a leader in interstitial fluid (ISF)-based diagnostics, today announced a new appointment to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO). Rene Veloso Chief Investment Officer “The addition of Rene to our already …

Duracell® batteries will be integrated into KIFFIK Biomonitoring Devices, such as health monitors, that detect various biomarkers in the body. [Providence, RI, 01/29/2025] – KIFFIK Biomedical and Duracell U.S. Operations, Inc. (“Duracell”) have agreed to collaborate and assess the integration of long-lasting, efficient power solutions with cutting-edge biomonitoring technology. This is good news for patients and the public communities, as the partnership’s goal is to enhance the precision and dependability of health monitoring systems around the globe, ultimately benefitting users in hospitals, high-performance sports, the military, and at home with …